NASDAQ Framework: Agios Pharmaceuticals Inc.
Biopharmaceutical company developing cellular metabolism therapies 1.
1: We feel now is a pretty good time to analyse Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) business as it appears the company may be on the cusp of a considerable accomplishment. Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. With the latest financial year loss of US$352m and a trailing-twelve-month loss of US$353m, the US$2.7b market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Agios Pharmaceuticals' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. View Source
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, that focuses on discovering and developing medicines in the field of cellular metabolism, particularly for genetically defined diseases such as hemolytic anemias 234. Founded in 2007 by Lewis Cantley, Tak Mak, and Craig Thompson, the company has made significant strides in pioneering therapies, including its lead product PYRUKYND (mitapivat) 56. Agios has a market capitalization of approximately $2.7 billion and is on the verge of profitability, with analysts predicting it will turn a profit in 2024 78. The company operates with no debt, relying solely on equity investment, which reduces investment risk 9.
2: We feel now is a pretty good time to analyse Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) business as it appears the company may be on the cusp of a considerable accomplishment. Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. With the latest financial year loss of US$352m and a trailing-twelve-month loss of US$353m, the US$2.7b market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Agios Pharmaceuticals' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. View Source3: Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.[3] The company was founded in 2008 (or 2007)[4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[2][5] The company tendered an initial public offering in July 2013.[6]: Table 1 View Source4: Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. View Source5: Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.[3] The company was founded in 2008 (or 2007)[4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[2][5] The company tendered an initial public offering in July 2013.[6]: Table 1 View Source6: Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. View Source7: We feel now is a pretty good time to analyse Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) business as it appears the company may be on the cusp of a considerable accomplishment. Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. With the latest financial year loss of US$352m and a trailing-twelve-month loss of US$353m, the US$2.7b market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Agios Pharmaceuticals' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. View Source8: Consensus from 8 of the American Biotechs analysts is that Agios Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$128m in 2024. So, the company is predicted to breakeven approximately 12 months from now or less. We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 14% is expected, which is relatively reasonable. However, if this rate turns out to be too buoyant, the company may become profitable later than analysts predict. View Source9: Before we wrap up, there’s one aspect worth mentioning. Agios Pharmaceuticals currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company. View Source
NO
Agios Pharmaceuticals Inc. is not still led by its founders, nor are the founders heavily involved. The current CEO is Brian Goff, who was appointed in August 2022 10.
Agios Pharmaceuticals Inc. is not still led by its founders, nor are the founders heavily involved. The current CEO is Brian Goff, who was appointed in August 2022 10.
10: As of August 2022[update], Agios' CEO is Brian Goff.[13] View Source
MEDIUM RISK
Agios Pharmaceuticals Inc. is currently operating with no debt, which reduces the financial risk typically associated with loss-making biotechs 11. However, the company has been amplifying its losses, with a trailing-twelve-month loss of $353 million 12. Despite this, analysts expect the company to turn profitable in 2024, which indicates a positive outlook but also highlights the current financial strain 13. Therefore, while the absence of debt is a positive factor, the ongoing losses and the reliance on future profitability place Agios Pharmaceuticals in a medium-risk category.
Agios Pharmaceuticals Inc. is currently operating with no debt, which reduces the financial risk typically associated with loss-making biotechs 11. However, the company has been amplifying its losses, with a trailing-twelve-month loss of $353 million 12. Despite this, analysts expect the company to turn profitable in 2024, which indicates a positive outlook but also highlights the current financial strain 13. Therefore, while the absence of debt is a positive factor, the ongoing losses and the reliance on future profitability place Agios Pharmaceuticals in a medium-risk category.
11: Before we wrap up, there’s one aspect worth mentioning. Agios Pharmaceuticals currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company. View Source12: We feel now is a pretty good time to analyse Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) business as it appears the company may be on the cusp of a considerable accomplishment. Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. With the latest financial year loss of US$352m and a trailing-twelve-month loss of US$353m, the US$2.7b market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Agios Pharmaceuticals' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. View Source13: Consensus from 8 of the American Biotechs analysts is that Agios Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$128m in 2024. So, the company is predicted to breakeven approximately 12 months from now or less. We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 14% is expected, which is relatively reasonable. However, if this rate turns out to be too buoyant, the company may become profitable later than analysts predict. View Source
14: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Has Found A Path To Profitability We feel now is a pretty good time to analyse Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) business as it appears the... Simply Wall St. • 9 hours ago AGIO -3.08% Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the GlobeNewswire • 6 days ago AGIO -3.08% Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains? Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. Zacks • 30 days ago AGIO -3.08% Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than... Simply Wall St. • last month AGIO -3.08% Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress – ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., June 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasd GlobeNewswire • last month AGIO -3.08% Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound? Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month AGIO -3.08% Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO) On June 5, 2024, Brian Goff, Chief Executive Officer of Agios Pharmaceuticals Inc (NASDAQ:AGIO), executed a sale of 12,115 shares of the company. GuruFocus.com • last month AGIO -3.08% Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Healthcare Conference has been updated to Monday, June 10, 2024 at 8:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website a GlobeNewswire • last month AGIO -3.08% Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden. Zacks • last month AGIO -3.08% ARQT Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia – Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures of Reduction of Transfusion Burden Compared to Placebo – – ENERGIZE-T is the First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia – – As Part of Global Submission Strategy, GlobeNewswire • last month AGIO -3.08% Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A r GlobeNewswire • last month AGIO -3.08% Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021. Zacks • last month AGIO -3.08% ARQT Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open. Investor's Business Daily • last month AGIO -3.08% Are Medical Stocks Lagging Lantheus (LNTH) This Year? Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year. Zacks • last month LNTH AGIO -3.08% Agios cashes in on cancer drug again with $905M Royalty Pharma deal The deal involves royalties for a brain cancer drug Agios previously sold off and that Royalty Pharma thinks could generate more than $1 billion in U.S. sales. BioPharma Dive • last month AGIO -3.08% Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty – Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain Revenue Thresholds – – Agios Retains Rights to $200 Million Milestone Payment from Servier upon FDA Approval of Vorasidenib – – In Total, Agios to Receive $1.1 Billion in Payments upon FDA Approval of Vorasidenib; PDUFA Action Date of August 20, 2024 – CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) - GlobeNewswire • last month AGIO -3.08% How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43% The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Zacks • last month AGIO -3.08% Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress – Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease – – Agios to Webcast Virtual Investor Event on June 16, 2024, at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a GlobeNewswire • 2 months ago AGIO -3.08% Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High? The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Zacks • 2 months ago AGIO -3.08% Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of GlobeNewswire • 2 months ago AGIO -3.08% View Source15: Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. View Source16: Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress View Source17: Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia View Source
Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]. Key milestones include the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia and the Phase 3 ENERGIZE-T study in transfusion-dependent thalassemia, both of which demonstrated significant efficacy [fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]. Key milestones include the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia and the Phase 3 ENERGIZE-T study in transfusion-dependent thalassemia, both of which demonstrated significant efficacy [fERROR][fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]. Key milestones include the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia and the Phase 3 ENERGIZE-T study in transfusion-dependent thalassemia, both of which demonstrated significant efficacy [fERROR][fERROR][fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]. Key milestones include the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia and the Phase 3 ENERGIZE-T study in transfusion-dependent thalassemia, both of which demonstrated significant efficacy [fERROR][fERROR][fERROR][fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]. Key milestones include the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia and the Phase 3 ENERGIZE-T study in transfusion-dependent thalassemia, both of which demonstrated significant efficacy [fERROR][fERROR][fERROR][fERROR]. Additionally, Agios plans to leverage its strong financial position, characterized by zero debt, to support ongoing and future clinical trials and commercialization efforts [fERROR]Agios Pharmaceuticals Inc. has outlined a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its lead product, PYRUKYND (mitapivat), and other promising therapies. The company aims to achieve profitability by 2024, driven by its innovative treatments for hemolytic anemias and other genetically defined diseases [fERROR][fERROR][fERROR]. Key milestones include the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia and the Phase 3 ENERGIZE-T study in transfusion-dependent thalassemia, both of which demonstrated significant efficacy [fERROR][fERROR][fERROR][fERROR]. Additionally, Agios plans to leverage its strong financial position, characterized by zero debt, to support ongoing and future clinical trials and commercialization efforts [fERROR].